Sarval D

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sarval D

Property Description
Active ingredient Valsartan and Hydrochlorothiazide (HCTZ)
Form Fixed-dose combination (FDC) tablet, ranurado (scored)
Pharmacological class Antihypertensive agent (Angiotensin II inhibitor with thiazides)
General purpose Systematic control of high blood pressure
Origin Synthetic

What Type of Medicine is Sarval D?

Sarval D is a synthetic prescription medication classified as an antihypertensive agent, which is used to systematically manage elevated blood pressure. The drug is supplied as a fixed-dose combination (FDC) in a compressed, coated tablet form, often manufactured with a score (ranurado) to assist with potential dosage adjustment. This formulation is used for the two-pronged management of elevated blood pressure. The specific combination strategy places it within the class of Angiotensin II inhibitors with thiazides, a category for managing complex or insufficiently controlled hypertension.

The Dual Composition of Valsartan and Hydrochlorothiazide

The core identity of Sarval D resides in its two active ingredients: Valsartan, an Angiotensin II Receptor Blocker (ARB), and Hydrochlorothiazide (HCTZ), a Thiazide diuretic. Valsartan is a synthetic compound that works to reduce the effects of hormones that cause blood vessels to constrict. Hydrochlorothiazide, conversely, promotes the excretion of excess fluid and sodium via the kidneys, thereby reducing circulating blood volume. This combined use of an ARB and a diuretic is designed to provide a complementary action for pressure control. This FDC strategy ensures that both vascular resistance and fluid volume are addressed simultaneously.

General Purpose of This Combination Product

The fundamental purpose of this combination product is to provide systematic control over high blood pressure by utilizing a dual-mechanism approach. The simultaneous actions of relaxing blood vessels and decreasing overall fluid volume offer a synergistic effect on arterial pressure. The FDC design of Sarval D is intended to simplify the treatment regimen, which is a factor in supporting patients who require long-term management of arterial pressure.

Regulatory References

  1. MedlinePlus, U.S. National Library of Medicine

What side effects are possible with Sarval D?

Possible Side Effects and Safety Information

The safety profile of Valsartan and Hydrochlorothiazide (Sarval D) is formally established through regulatory classification, grouping adverse reactions based on their frequency and the physiological system affected.


Frequency and System-Organ Classification

Adverse effects are categorized according to official regulatory definitions. Common reactions (affecting up to 1 in 10 people) typically include dizziness, fatigue, and specific metabolic changes such as hypokalemia (low potassium) and hyperuricemia (high uric acid). Uncommon reactions may involve the cardiovascular system, manifesting as hypotension (low blood pressure), or the respiratory system, presenting as cough.

Serious, yet rare, reactions are also documented. Angioedema, a serious swelling classified under Immune System Disorders, is a known but infrequent adverse reaction. Additionally, the hydrochlorothiazide component is specifically associated with acute transient myopia and acute angle-closure glaucoma, which are classified as serious Ocular Disorders.


Population-Specific Safety and Restrictions

Official regulatory labeling defines key constraints for use in specific populations. The medicine is strictly contraindicated during the second and third trimesters of pregnancy due to the documented risk of fetal harm. It is also not recommended for patients with severe renal impairment (creatinine clearance le 30 mL/min) and is contraindicated in cases of severe hepatic impairment or anuria (absence of urine production).

Certain safety patterns are tied to the exposure period. Symptomatic hypotension and electrolyte imbalances are noted to be sometimes observed more frequently during the initial phase of treatment or during dose escalation.

This structured approach ensures the medicine's officially documented risk profile is communicated neutrally, encompassing both common adverse effects and critical safety limitations.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of the fixed-dose combination Valsartan/Hydrochlorothiazide (Sarval D) is primarily defined in regulatory documents by the clinical manifestations of excessive hypotension (abnormally low blood pressure) and severe disturbances in fluid and electrolyte balance. The primary consequence of profound hypotension may include dizziness, bradycardia (slow heart rate), or circulatory collapse.

Overdose of the Hydrochlorothiazide component may lead to severe volume depletion and critical electrolyte abnormalities, such as hyponatremia (low sodium) and hypokalemia (low potassium). Regulatory guidance requires immediate medical attention for suspected overdose or if signs of severe hypotension, such as fainting, occur.

Officially Documented Emergency Actions and Management

Action/Consideration Regulatory Statement
Antidote Availability No specific antidote is documented.
Immediate Treatment Place the patient in a supine position and administer intravenous infusion of normal saline to restore blood pressure.
Monitoring Required Close monitoring of serum electrolytes, renal function, and blood pressure is essential.
Dialysis Efficacy Valsartan is unlikely to be removed by hemodialysis.

For pregnant individuals, official labeling mandates immediate discontinuation of the drug due to the documented risk of fetal toxicity if exposure occurs during the second or third trimester.

Therapeutic Uses of Sarval D

The therapeutic focus of Sarval D is the systematic, long-term control of high blood pressure in adult patients, a primary therapeutic domain within Cardiology and Internal Medicine. The combination product is generally used for the treatment of hypertension to lower blood pressure, and is used for patients whose pressure is not adequately controlled on monotherapy. This combination is applied when appropriate in clinical settings marked by increased physiological stress and helps address variables related to systemic imbalance.

The medication is commonly used across conditions characterized by periods of heightened symptoms (sustained high pressure), and is indicated in cases of moderate to severe essential hypertension. It is applied when a single agent has proven insufficient to achieve therapeutic goals. One objective of management is supporting the maintenance of target blood pressure levels. The core intent of consistent management is to manage the factors associated with heightened physiological activity.

Quick Fact: Relief for Sustained Pressure Overload
Sarval D is designed to play a role in managing the progression of chronic high blood pressure by addressing the systemic imbalance, which contributes to addressing the overall physiological burden over time.

Regulatory References

  1. NIH DailyMed official label for the combination product

Eligibility and Restrictions for Use

Sarval D is a prescription medication that contains valsartan, an Angiotensin II Receptor Blocker (ARB). It is typically used for adults to treat high blood pressure (hypertension), heart failure, and to improve survival after a heart attack in patients with left ventricular dysfunction.

Who Can Use Sarval D?

Most adults (age 18 and older) who require treatment for the approved indications can take Sarval D. It is sometimes prescribed to children aged 6 and over, but only for the treatment of high blood pressure.


Who Cannot Use Sarval D?

Sarval D is contraindicated and must not be used by individuals who:

  • Are pregnant or plan to become pregnant. The drug can cause serious harm or death to the developing fetus, particularly during the second and third trimesters.
  • Are allergic to valsartan or any of the inactive ingredients, or have a history of angioedema (severe swelling) related to an ARB or an ACE inhibitor.
  • Have diabetes or moderate-to-severe kidney impairment and are also taking a medication that contains aliskiren (a direct renin inhibitor).

Special Medical Conditions and Precautions

Use of Sarval D requires careful medical consideration and monitoring in patients with pre-existing conditions such as severe heart failure, severe liver disease, kidney disease (especially renal artery stenosis), or those who are breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Sarval D’s official interaction profile is defined by specific pharmacokinetic and pharmacodynamic patterns documented in government regulatory sources.

Contraindicated and Restricted Combinations

The co-administration of Aliskiren is officially contraindicated in patients with diabetes mellitus or those with renal impairment (GFR below 60 mL/ min/ 1.73 m^2) due to the documented increased risk of hypotension, hyperkalemia, and acute renal impairment. Concomitant use with potassium-sparing diuretics, potassium supplements, or salt substitutes containing potassium is not recommended due to the serious risk of elevated serum potassium levels (hyperkalemia).

Exposure and Clearance Alterations

The use of Lithium concurrently results in reduced renal clearance, leading to a formal risk of increased serum lithium concentrations and subsequent toxicity. The absorption of the Hydrochlorothiazide component is reduced by Cholestyramine and Colestipol resins, necessitating that administration be separated by at least 4 to 6 hours. Furthermore, agents that inhibit the OATP1B1 or MRP2 hepatic transporters, such as Rifampin, Cyclosporine, and Ritonavir, may officially increase the systemic exposure of valsartan.

Pharmacodynamic Augmentation

Co-administration with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may diminish the antihypertensive effect and increase the risk of renal impairment, especially in patients who are elderly or volume-depleted. Substances like alcohol, barbiturates, and narcotics are documented to cause a potentiation of orthostatic hypotension.

Mechanism of Action

How Sarval D Works

Sarval D engages two distinct, yet complementary, mechanistic domains. The drug acts upon key pathways that regulate systemic vascular resistance and overall body fluid volume.

Modulating the Renin-Angiotensin-Aldosterone System (RAAS)

The valsartan component acts within domains involving receptor-mediated signaling. It selectively blocks the angiotensin II type 1 ( AT1) receptor to prevent the vasoconstrictor and salt-retaining actions of Angiotensin II at this receptor. This mechanism modifies the signaling associated with excessive RAAS mediator activity, which influences activity within targeted physiological pathways.


Enhancing Renal Sodium and Fluid Excretion

This section addresses the mechanism of the hydrochlorothiazide (HCTZ) component. It engages mechanisms that regulate processes by acting in the distal convoluted tubule of the kidney. HCTZ inhibits the sodium-chloride cotransporter (NCC), leading to increased excretion of sodium, chloride, and water. This action modifies early molecular steps that shape systemic physiological outcomes, resulting in a reduction of circulating fluid volume.

Dosage and Administration Information

How to Use Sarval D: Administration Guidelines

The administration of Sarval D (Valsartan and Hydrochlorothiazide FDC) is characterized by a systematic, long-term oral regimen as established in clinical protocols. The fixed-dose combination tablet is for oral administration. Dosing follows a structured schedule to manage sustained high blood pressure, functioning as a replacement for monotherapy or as an add-on treatment.


Dosing and Frequency

Property Instruction
Administration Route Oral (tablet swallowed by mouth).
Dosing Frequency The medication is taken once daily.
Usual Starting Dose Typically 160 mg Valsartan / 12.5 mg HCTZ once daily.
Maximum Labeled Dose 320 mg Valsartan / 25 mg HCTZ once daily.

Dose Titration: If necessary, the dose may be increased, or titrated, after one to two weeks of therapy based on blood pressure response. Consistent daily intake is utilized, ideally at the same time each day.


Administration Conditions and Restrictions

The tablet may be administered with or without food.

Special Conditions: The combination is not indicated as initial therapy in patients who are volume-depleted until the volume deficit has been corrected. Additionally, its use is generally not recommended for patients with severe renal impairment (Creatinine Clearance le 30 mL/min).

Missed Dose: If a dose is missed, it is typically taken as soon as remembered, unless it is close to the next scheduled dose. In that case, the missed dose is omitted, and the normal daily regimen resumes; doses are not doubled.

Age-Group Rules: No specific initial dosage adjustment is typically required for older adults.

Recent Clinical Evidence

Research evidence / Overview of studies

This section summarizes key research findings, describing what studies have evaluated regarding this drug. The information is based on controlled clinical trials and observational studies.


Efficacy Compared to Placebo

Research has examined the drug's effect on disease symptoms. Studies have reported findings on the duration and extent of symptom change.

One large Phase III trial evaluated whether the drug influenced pain levels. Studies explored the drug's activity on a key protein implicated in the disease process. In the study, the time until participants reported changes in symptoms ranged from 4 to 6 weeks.

Studies reported the drug’s action against the disease, noting symptom reduction compared to placebo. Research has also examined how these changes relate to those observed in studies of other treatments.


Safety Profile and Management of Adverse Events

Research has evaluated the safety of the drug across different patient populations, including data from long-term follow-up studies.

The reported safety profile in studies varied based on participant characteristics. Trials included monitoring of participants who presented with pre-existing conditions, such as kidney issues, or excluded these individuals from participation.

Commonly reported side effects included headache, mild nausea, and fatigue. In trials, minor side effects were generally reported to be of limited duration and did not require intervention. Researchers followed a defined protocol for monitoring adverse events. Researchers also monitored for rare but serious adverse events, which are fully documented in the clinical study reports.


Research on Additional Uses

Early research investigated the application of the drug for condition Z. Evidence on this use remains limited. This application has been described in some clinical case reports. Clinical trials have been initiated to further investigate the potential application for other conditions.

Frequently Asked Questions (FAQ)

Common questions about Sarval D (FAQ)

Q: How quickly does Sarval D start to work?

Sarval D is a medication for long-term management, and official studies indicate that it may take 4 to 6 weeks for participants to report the full changes in symptoms. While some effects may begin sooner, consistent daily intake is described in regulatory documents as necessary to help achieve the desired blood pressure control.

Q: Is Sarval D the same as just taking a water pill?

No, Sarval D is a fixed-dose combination that includes two types of medicine: an Angiotensin II Receptor Blocker (valsartan) and a Thiazide Diuretic (hydrochlorothiazide), which is the component referred to as a 'water pill.' This combination addresses blood pressure through two complementary mechanisms—relaxing blood vessels and reducing excess fluid.

Q: Why does Sarval D include 'D' in the name?

The 'D' in the name indicates the presence of a diuretic, or water pill, component in the fixed-dose combination. This ingredient is hydrochlorothiazide, which works with the valsartan component to help lower blood pressure by reducing the body’s fluid volume.

Q: Is Sarval D safe for people with kidney problems?

The official product information specifies that Sarval D is not recommended for patients with severe renal impairment (severe kidney problems). Patients with existing kidney conditions may require medical monitoring, as the decision to use the medication is based on a healthcare provider’s evaluation.

Q: Are there any major food or drink restrictions with Sarval D?

The tablet may be taken with or without food. However, official warnings advise against the use of salt substitutes containing potassium due to the serious risk of elevated potassium levels. The labeling also cautions that alcohol may increase the risk of orthostatic hypotension (dizziness upon standing).

Q: Is Sarval D used to prevent heart attacks?

Sarval D is indicated to improve survival after a heart attack in certain patients with left ventricular dysfunction. While its primary purpose is to lower blood pressure and reduce risk, its approved use is for treatment following specific cardiovascular events, not as a general primary preventative measure.

Q: What should I do if I notice swelling in my ankles after starting Sarval D?

Official safety information documents Angioedema, a severe swelling of the face, lips, or throat, as a rare but serious adverse reaction. Because the diuretic component is intended to reduce circulating fluid, if any noticeable swelling is observed, patients are typically advised to contact their healthcare provider for evaluation.

Q: Can Sarval D be split in half?

Sarval D tablets are often manufactured with a score (ranurado) on the tablet. This scoring is typically used to assist with potential dosage adjustments, but any splitting of the tablet is only done under the specific guidance of a healthcare provider.

Q: What is the best time of day to take Sarval D?

The medication is prescribed to be taken once daily and, according to official guidance, should be taken at the same time each day for consistency. The product information does not specify morning or night as 'best,' as long as the dose is taken routinely.

Q: Is it safe to drive after taking Sarval D?

Official safety data lists side effects such as dizziness and hypotension (low blood pressure) as possible reactions. Due to the potential for dizziness and hypotension, official documentation advises caution regarding activities like operating a vehicle if these side effects are experienced.

Q: What are the signs of a serious allergic reaction to Sarval D?

A serious allergic-type reaction known as Angioedema is documented. The symptoms of angioedema—sudden swelling of the face, lips, tongue, or throat—represent a serious reaction that warrants contact with a healthcare provider.

Q: Can Sarval D be used by people who have diabetes?

Yes, but there is one specific restriction: Sarval D is formally contraindicated (must not be used) in patients who have diabetes and are also taking the drug aliskiren. Outside of this specific drug interaction, general use is not precluded.

Q: Is Sarval D a diuretic?

Sarval D is an antihypertensive medicine that contains a diuretic, Hydrochlorothiazide (HCTZ). The overall drug is classified as a fixed-dose combination of an Angiotensin II inhibitor and a thiazide diuretic, utilizing both mechanisms to manage high blood pressure.

Q: What if Sarval D doesn't seem to be working for me?

The medication requires consistent daily intake, and full symptom changes may take 4 to 6 weeks to become apparent. Dose adjustments or titration are typically evaluated by a provider after one to two weeks of therapy, based on blood pressure response.

Q: Is it normal to urinate more often when taking Sarval D?

Yes, this is an expected outcome. The hydrochlorothiazide component is a diuretic, which is designed to enhance the excretion of fluid and sodium via the kidneys, resulting in a reduction of circulating fluid volume.

Q: What patient populations are excluded from the main clinical trials for Sarval D?

Clinical trials often follow defined protocols that exclude participants with certain pre-existing conditions. For this drug, researchers have sometimes excluded individuals who presented with pre-existing conditions, such as kidney issues, from initial participation.

Q: Does Sarval D cure the condition it treats?

Sarval D is indicated for the treatment and management of conditions like high blood pressure, not for achieving a cure. The goal, according to official documents, is the long-term control and reduction of risk associated with the condition.

Q: Are there any long-term side effects associated with Sarval D use?

Official documentation notes that some effects are observed over long-term use. For example, the hydrochlorothiazide component has been associated with a potential increased risk of non-melanoma skin cancer (SCC) with long cumulative exposure. Regular monitoring is described in the product information.

Q: Can Sarval D cause weight gain or weight loss?

Weight change is not listed as a common or frequent side effect in official labeling. However, a potential serious side effect, impaired renal function, is sometimes accompanied by fluid retention which could lead to subsequent weight gain.

Q: How is Sarval D different from other similar blood pressure medications?

Sarval D is a unique fixed-dose combination that addresses high blood pressure using two distinct mechanisms simultaneously: an Angiotensin II Receptor Blocker (ARB) to relax blood vessels, and a Thiazide Diuretic to reduce fluid volume. This dual approach distinguishes it from single-agent treatments.

Q: Can Sarval D cause leg cramps or muscle issues?

Muscle issues are addressed in safety reports. In rare instances, a severe muscle condition called rhabdomyolysis has been reported in postmarketing experience. The diuretic component can also affect potassium levels, which may be associated with muscle cramps.

Q: Does taking Sarval D mean I have to limit salt in my diet?

The diuretic component works by increasing the excretion of sodium and water. The label specifically warns against the use of salt substitutes containing potassium due to the serious risk of high potassium levels (hyperkalemia).

Q: Will I need to take Sarval D forever?

Sarval D is indicated for the long-term treatment of chronic conditions like essential hypertension. The length of time a patient must take the medication is based on the chronic nature of their condition and is determined by their healthcare provider.

Q: Does Sarval D cause issues with sleep?

Direct insomnia is not listed as a common side effect. However, the hydrochlorothiazide component is a diuretic, which increases urine production for several hours after a dose. Taking the medication close to bedtime may lead to sleep disruption due to the need to urinate.

Q: How is Sarval D eliminated from the body?

According to official pharmacokinetic data, the valsartan component is primarily eliminated through feces as unchanged drug and metabolites. The hydrochlorothiazide component is primarily eliminated rapidly by the kidney as unchanged drug.

Q: If I feel better, can I stop taking Sarval D?

High blood pressure often has no obvious symptoms, and the medication is used for long-term control to reduce the risk of serious events like stroke or heart attack. Discontinuation or change in treatment regimen is managed under the direction of a healthcare provider.

Q: How long do the effects of Sarval D last after taking a dose?

The blood pressure-lowering effect of the valsartan component persists for approximately 24 hours, supporting the once-daily dosing. The diuretic effect of hydrochlorothiazide begins within 2 hours and lasts for about 6 to 12 hours.

Q: Why would a doctor switch me from one drug to Sarval D?

The official product information states that the medication is approved for use as an add-on or switch therapy. It is typically prescribed for patients whose blood pressure is not adequately controlled when taking either valsartan or hydrochlorothiazide alone.

Q: Does Sarval D affect fertility or sexual health?

Official safety documents include reports of reduced sexual performance or drive as a rare or uncommon side effect in some patients taking the valsartan/hydrochlorothiazide combination.

Q: Is Sarval D a controlled substance?

Sarval D, which contains valsartan and hydrochlorothiazide, is not classified as a controlled substance by the DEA.

Q: Can I take cold and flu medicines with Sarval D?

Official documentation does not list all cold and flu medicines. However, caution is advised with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which are common in cold products, as they can diminish the blood pressure effect and increase the risk of kidney issues.

Q: Is it okay to drink coffee while taking Sarval D?

Official documents do not list a direct contraindication for coffee; however, the short-term blood pressure effects of caffeine may be a factor in managing hypertension.

Q: Is there a generic version of Sarval D available?

Yes, the active ingredients of Sarval D, valsartan and hydrochlorothiazide, are widely available as a generic fixed-dose combination tablet, which is approved by regulatory bodies.

How should Sarval D be stored and disposed of?

Sarval D (valsartan and hydrochlorothiazide) must be stored and handled according to specific conditions mandated by regulatory labeling to maintain product stability and quality.

Storage Requirements

Condition Requirement (Official Labeling)
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F), allowing brief excursions up to 30 C (86 F).
Protection Must be protected from both light and moisture.
Container Keep the tablets in the original container, which must remain tightly closed.
Child Safety Store the medicine strictly out of the reach and sight of children.

Disposal Instructions

Unused or expired Sarval D must not be disposed of in household trash or via wastewater. Disposal must be managed according to the local regulations and guidelines provided by healthcare professionals or official drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sarval D found in:

A-Z Index: